UNSPSC 51101938: Tebuquine

This classification denotes an antimalarial agent with the molecular formula C26H25Cl2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 699Q1XT4EN, chemically known as wr 228,258 but generally known as tebuquine, which bears US NIH Compound Identifier 71991. European Medicines Agency schedules Tebuquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10855MIG. The term TEBUQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23).

UNSPSC 51101938 Tebuquine, a Commodity code, does not map to the work actually being solicited under it in recent state and local opportunities. The code nominally describes a specific antimalarial pharmaceutical, but recent solicitations posted under this code instead cover a broad range of medical supplies, pharmaceuticals, and health-system procurement — including naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, emergency medical supplies, and generic multi-source pharmaceuticals and over-the-counter products. The mismatch between the code's narrow pharmaceutical scope and the diverse health procurement appearing in the recent-opportunities block suggests either administrative misclassification or that state and local procurement offices are using this code as a general placeholder for pharmacy and medical-supply acquisitions rather than for tebuquine specifically. This represents a significant disconnect from the code's intended commodity definition.

Issuing bodies include county health systems (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments and purchasing offices (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across Minnesota and Oregon). Recent opportunities span Florida, Texas, Minnesota, and Oregon, with activity in the first half of 2026 including an IFB from Seminole County for naloxone and drug deactivation systems (response deadline July 26, 2023, though the posting date of June 30, 2026 suggests a data anomaly), a Request for Information from Texas HHS on direct-to-manufacturer prescription programs (due April 3, 2026), an IFB from the City of Tampa for medical and first aid supplies to the Fire Department Rescue Division with an estimated value of $700,000 and SLBE set-aside (due March 13, 2026), and an RFP from MMCAP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). The code shows activity but lacks coherent focus around tebuquine or any single commodity class.